Teva Will Inherit OAI Status Of Andrx' Oral Contraceptives
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will continue to block approval of Andrx' oral contraceptives until manufacturing issues are resolved despite the company's intention to transfer its pending ANDAs to Teva